OpenLB
Open Library of Bioscience
Advanced Search
Neurology. Clinical practice
Apr, 2022;12 (2): 131-138.

Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease.

Andrew McGarry, Peggy Auinger, Karl D Kieburtz, Amy-Lee Bredlau, Steven M Hersch, H Diana Rosas
Author Information
  1. Andrew McGarry: Department of Neurology (AM), Cooper University Healthcare at Rowan University, Camden, NJ; Center for Health and Technology (PA), University of Rochester, NY; Department of Neurology (KDK), University of Rochester, NY; University of Rochester (A-LB), NY; and Department of Neurology (SMH, HDR), Harvard Medical School, Boston, MA.
  2. Peggy Auinger: Department of Neurology (AM), Cooper University Healthcare at Rowan University, Camden, NJ; Center for Health and Technology (PA), University of Rochester, NY; Department of Neurology (KDK), University of Rochester, NY; University of Rochester (A-LB), NY; and Department of Neurology (SMH, HDR), Harvard Medical School, Boston, MA.
  3. Karl D Kieburtz: Department of Neurology (AM), Cooper University Healthcare at Rowan University, Camden, NJ; Center for Health and Technology (PA), University of Rochester, NY; Department of Neurology (KDK), University of Rochester, NY; University of Rochester (A-LB), NY; and Department of Neurology (SMH, HDR), Harvard Medical School, Boston, MA.
  4. Amy-Lee Bredlau: Department of Neurology (AM), Cooper University Healthcare at Rowan University, Camden, NJ; Center for Health and Technology (PA), University of Rochester, NY; Department of Neurology (KDK), University of Rochester, NY; University of Rochester (A-LB), NY; and Department of Neurology (SMH, HDR), Harvard Medical School, Boston, MA.
  5. Steven M Hersch: Department of Neurology (AM), Cooper University Healthcare at Rowan University, Camden, NJ; Center for Health and Technology (PA), University of Rochester, NY; Department of Neurology (KDK), University of Rochester, NY; University of Rochester (A-LB), NY; and Department of Neurology (SMH, HDR), Harvard Medical School, Boston, MA.
  6. H Diana Rosas: Department of Neurology (AM), Cooper University Healthcare at Rowan University, Camden, NJ; Center for Health and Technology (PA), University of Rochester, NY; Department of Neurology (KDK), University of Rochester, NY; University of Rochester (A-LB), NY; and Department of Neurology (SMH, HDR), Harvard Medical School, Boston, MA.
PMID: 35747889 DOI: 10.1212/CPJ.0000000000001161

Abstract

Background and Objectives: Suicidality is a common concern in the routine care of persons with Huntington disease (HD) and for the many participants in HD clinical trials. In a previous analysis, we identified baseline and time-dependent factors associated with suicidal ideation and attempts from 2CARE, a large, randomized, double-blind clinical trial.
Methods: The present analysis extends our prior methodology to 2 other large interventional HD clinical trials, CARE-HD and CREST-E.
Results: We observed relationships across studies between suicidality events and prior suicidal ideation at baseline, antidepressant/anxiolytic use, chorea, increasing age, and several domains in the Unified Huntington Disease Rating Scale (UHDRS) Behavioral Assessment (depressed mood, low self-esteem, aggression, and active suicidality).
Discussion: These data may form the basis for a subscale of demographic and UHDRS items with the potential for prospectively identifying suicidality risk in HD clinics and clinical trials.
Trial Registration Information: 2CARE and CREST are registered at clinicaltrials.gov. 2CARE NCT00608881, registered February 6, 2008; first enrollment March 2008. CREST-E NCT00712426, registered July 10, 2008; first enrollment September 2009. CARE-HD, not registered; first enrollment July 1997.

Associated Data

ClinicalTrials.gov | NCT00608881; NCT00712426

References

  1. Neurology. 2001 Aug 14;57(3):397-404 [PMID: 11502903]
  2. Front Behav Neurosci. 2014 Apr 02;8:103 [PMID: 24765067]
  3. J Clin Child Adolesc Psychol. 2015;44(5):751-61 [PMID: 24871489]
  4. J Affect Disord. 2018 Oct 1;238:563-569 [PMID: 29940520]
  5. Neurology. 2019 Apr 2;92(14):e1643-e1651 [PMID: 30850442]
  6. J Clin Exp Neuropsychol. 2017 Sep;39(7):694-706 [PMID: 27892808]
  7. Neurology. 2017 Jan 10;88(2):152-159 [PMID: 27913695]
  8. J Huntingtons Dis. 2016 Dec 15;5(4):395-403 [PMID: 27983566]
  9. J Huntingtons Dis. 2017;6(1):73-78 [PMID: 28339399]
  10. J Huntingtons Dis. 2020;9(4):359-369 [PMID: 33164940]
  11. Pharmaceuticals (Basel). 2010 Aug 30;3(9):2861-2883 [PMID: 27713380]
  12. Am J Med Genet. 1986 Jun;24(2):305-11 [PMID: 2940862]
  13. Mov Disord. 1996 Mar;11(2):136-42 [PMID: 8684382]
  14. Am J Psychiatry. 2018 Oct 1;175(10):951-960 [PMID: 29792051]
  15. Neurology. 2017 Aug 08;89(6):594-601 [PMID: 28701493]
Journal Article
Article has an altmetric score of 10

Word Cloud

Created with Highcharts 10.0.0HDclinical2CAREregisteredHuntingtontrialsCARE-HDCREST-Esuicidality2008firstenrollmentSuicidalityanalysisbaselinesuicidalideationlargepriorDiseaseUHDRSJulyBackgroundObjectives:commonconcernroutinecarepersonsdiseasemanyparticipantspreviousidentifiedtime-dependentfactorsassociatedattemptsrandomizeddouble-blindtrialMethods:presentextendsmethodology2interventionalResults:observedrelationshipsacrossstudieseventsantidepressant/anxiolyticusechoreaincreasingageseveraldomainsUnifiedRatingScaleBehavioralAssessmentdepressedmoodlowself-esteemaggressionactiveDiscussion:datamayformbasissubscaledemographicitemspotentialprospectivelyidentifyingriskclinicsTrialRegistrationInformation:CRESTclinicaltrialsgovNCT00608881February6MarchNCT0071242610September20091997RiskFactorsAcrossClinicalTrials

Similar Articles

Cited By